NEW YORK (GenomeWeb) – Leerink on Monday initiated coverage of Myriad Genetics with a Market Perform rating and a $31 12-month price target on the company's stock.
In a research note, analyst Puneet Souda noted that while Myriad is still a dominant leader in hereditary cancer testing, it is still trying to stabilize that business in the wake of the 2013 US Supreme Court decision on gene patenting, while also diversifying its portfolio to drive future growth.